Shionogi starts pivotal Japanese trial of Akili's ADHD app

A Japanese language version of Akili Interactive's EndeavorRx ground-breaking digital therapy for attention deficit hyperactivity disorder (ADHD) has started a phase 3 trial, with results d

UK launches its 'Netflix-style' payment model for antibiotic...

The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline in the category.

Tivicay approved in Europe in new dispersible tablet for chi...

ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV.

Shionogi and Tetra expand partnership ahead of Alzheimer's t...

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.

Boehringer bags CHMP backing for Ofev in rare lung disease

UK's NHS to fund Shionogi's Mulpleo after backing from NICE ...

Shionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available to NHS patients across the UK after authorities in England and Scotland said it